Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 141 to 150 of 220 total matches.
In Brief: A New Endometrial Cancer Indication for Dostarlimab (Jemperli) (online only)
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
toxicity occurs
or up to 3 years. Dostarlimab should be given before
chemotherapy if they are both given ...
The immune checkpoint inhibitor dostarlimab-gxly
(Jemperli – GSK) has been approved by the FDA for
use in combination with carboplatin and paclitaxel
for treatment of adults with mismatch repair deficient
(dMMR) or microsatellite instability-high (MSI-H)
primary advanced or recurrent endometrial cancer.
Dostarlimab was recently granted regular approval
for treatment of adults with dMMR recurrent or
advanced endometrial cancer that progressed on
or following a prior platinum-containing regimen in
any setting and who are not candidates for curative
surgery or radiation.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e138 doi:10.58347/tml.2023.1683f | Show Introduction Hide Introduction
In Brief: Obecabtagene Autoleucel (Aucatzyl) - Another CAR-T Cell Immunotherapy for ALL (online only)
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024 (Issue 1718)
, AND COST — Cyclophosphamide and fludarabine lymphodepleting chemotherapy should be administered before ...
Obecabtagene autoleucel (Aucatzyl – Autolus), a
CD19-directed genetically modified autologous T cell
immunotherapy, has been approved by the FDA for
treatment of relapsed or refractory B-cell precursor
acute lymphoblastic leukemia (ALL) in adults. The
CAR T-cell immunotherapy products tisagenlecleucel
(Kymriah) and brexucabtagene auto-leucel (Tecartus)
were approved earlier for the same indication.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):e208 doi:10.58347/tml.2024.1718f | Show Introduction Hide Introduction
Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 23, 2018 (Issue 1545)
has been more
effective than chemotherapy for first-line treatment
of ALK-positive metastatic NSCLC.1 About 60 ...
The FDA has approved brigatinib (Alunbrig – Takeda),
an oral tyrosine kinase inhibitor, for treatment of
patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
who have progressed on or are intolerant to crizotinib
(Xalkori). Translocations of the ALK gene are found in
about 5% of lung cancers; they occur predominantly
in nonsmokers with adenocarcinoma. Brigatinib is the
third tyrosine kinase inhibitor to be approved for this
indication; ceritinib (Zykadia) and alectinib (Alecensa)
were approved earlier, and subsequently were...
Goserelin - Another LH-RH Analog for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Nov 02, 1990 (Issue 830)
COPYRIGHT LAWS
flutamide Eulexin of goserelin Cost goserelin for prostate cancer Cancer chemotherapy ...
The US Food and Drug Administration recently approved the marketing of goserelin acetate (Zoladex - ICI Pharma), an implant for palliative treatment of advanced prostate cancer. Goserelin acetate is a synthetic decapeptide luteinizing hormone-releasing hormone (LH-RH) analog similar to leuprolide (Lupron; Lupron Depot) (Medical Letter, 27:71, 1985).
Idarubicin
The Medical Letter on Drugs and Therapeutics • Sep 06, 1991 (Issue 852)
Cerubidine idarubicin for AML Cancer chemotherapy Antacids Adriamycin cytarabine daunorubicin doxorubicin ...
Idarubicin hydrochloride (Idamycin - Adria), an anthracycline structurally related to daunorubicin (Cerubidine, and others) and doxorubicin (Adriamycin, and others), was recently approved in the USA for treatment of acute myelogenous leukemia (AML) in adults.
In Brief: Brexucabtagene autoleucel (Tecartus) for Acute Lymphoblastic Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
chemotherapy (cyclophosphamide
and fludarabine).
CLINICAL STUDIES — FDA approval of the CD19-directed CAR ...
Brexucabtagene autoleucel (Tecartus – Kite) has
been approved by the FDA for treatment of adults
with relapsed or refractory B-cell precursor acute
lymphoblastic leukemia (ALL). It was previously
approved for treatment of relapsed or refractory
mantle cell lymphoma. Tecartus is an individualized
cellular product prepared from the patients own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. The CAR T-cell immunotherapy
tisagenlecleucel (Kymriah) was approved in 2017 for
treatment of relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e105-6 doi:10.58347/tml.2023.1678f | Show Introduction Hide Introduction
Flutamide For Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Jul 28, 1989 (Issue 797)
IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS
Cancer chemotherapy flutamide Cost of flutamide ...
Flutamide (Eulexin - Schering), an oral antiandrogen, is now available in the USA for treatment of metastatic prostate cancer. Flutamide is recommended by the manufacturer only for use concurrently with an analog of luteinizing hormone-releasing hormone (LHRH) such as leuprolide (Lupron - Medical Letter, 27:71, 1985).
Topotecan Hydrochloride for Metastatic Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • Oct 25, 1996 (Issue 986)
cisplatin carboplatin topotecan for ovarian Cancer chemotherapy Cytoxan Hycamtin Topotecan for metastatic ...
Topotecan hydrochloride (Hycamtin - SmithKline Beecham) was recently approved by the U.S. Food and Drug Administration for parenteral use as a single agent in patients with metastatic ovarian cancer refractory to other drugs. Initial treatment for metastatic ovarian cancer usually consists of cisplatin (Platinol) or carboplatin (Paraplatin) plus paclitaxel (Taxol) or cyclophosphamide (Cytoxan, and others).
Gliadel Wafers for Treatment of Brain Tumors
The Medical Letter on Drugs and Therapeutics • Sep 11, 1998 (Issue 1035)
COPYRIGHT LAWS
BiCNU Cancer chemotherapy carmustine Carmustine wafer for brain tumor Gliadel wafers ...
A biodegradable polymer 'wafer' (Gliadel - Rh ne-Poulenc Rorer) impregnated with the alkylating agent carmustine (BCNU; Bicnu) has been marketed in the USA for local treatment of recurrent glioblastoma multiforme that requires re-operation. The dime-sized polyanhydride wafers are implanted into the surgical cavity left behind after resection. Release of the alkylating agent directly into the area of the tumor bypasses the blood-brain barrier (H Brem and R Langer, Sci Med, 3:1, 1996).
Ceritinib (Zykadia) for Non-Small Cell Lung Cancer
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
patients and trials comparing it to
chemotherapy in treatment-naive and previouslytreated
patients ...
Ceritinib (Zykadia – Novartis), an oral tyrosine
kinase inhibitor, has received accelerated approval
from the FDA for treatment of patients with anaplastic
lymphoma kinase (ALK)-positive metastatic
non-small cell lung cancer (NSCLC) who have
progressed on or are intolerant to crizotinib (Xalkori).
It is the second tyrosine kinase inhibitor to be approved
for ALK-positive metastatic NSCLC; crizotinib was the
first. Translocations of the ALK gene are found in
about 5% of lung cancers; they occur predominantly
in nonsmokers with adenocarcinoma.